1
|
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C, Cohen AC, Hackett J, Shi J, Walker MG, Sun Z, Paietta E, Tallman MS, Cripe LD, Atwater S, Appelbaum FR, Radich JP. Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 2015; 10:e0118485. [PMID: 25884949 PMCID: PMC4401549 DOI: 10.1371/journal.pone.0118485] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Accepted: 12/31/2014] [Indexed: 11/18/2022] Open
Abstract
Single-cell network profiling (SCNP) data generated from multi-parametric flow cytometry analysis of bone marrow (BM) and peripheral blood (PB) samples collected from patients >55 years old with non-M3 AML were used to train and validate a diagnostic classifier (DXSCNP) for predicting response to standard induction chemotherapy (complete response [CR] or CR with incomplete hematologic recovery [CRi] versus resistant disease [RD]). SCNP-evaluable patients from four SWOG AML trials were randomized between Training (N = 74 patients with CR, CRi or RD; BM set = 43; PB set = 57) and Validation Analysis Sets (N = 71; BM set = 42, PB set = 53). Cell survival, differentiation, and apoptosis pathway signaling were used as potential inputs for DXSCNP. Five DXSCNP classifiers were developed on the SWOG Training set and tested for prediction accuracy in an independent BM verification sample set (N = 24) from ECOG AML trials to select the final classifier, which was a significant predictor of CR/CRi (area under the receiver operating characteristic curve AUROC = 0.76, p = 0.01). The selected classifier was then validated in the SWOG BM Validation Set (AUROC = 0.72, p = 0.02). Importantly, a classifier developed using only clinical and molecular inputs from the same sample set (DXCLINICAL2) lacked prediction accuracy: AUROC = 0.61 (p = 0.18) in the BM Verification Set and 0.53 (p = 0.38) in the BM Validation Set. Notably, the DXSCNP classifier was still significant in predicting response in the BM Validation Analysis Set after controlling for DXCLINICAL2 (p = 0.03), showing that DXSCNP provides information that is independent from that provided by currently used prognostic markers. Taken together, these data show that the proteomic classifier may provide prognostic information relevant to treatment planning beyond genetic mutations and traditional prognostic factors in elderly AML.
Collapse
Affiliation(s)
- Alessandra Cesano
- Nodality, Inc., South San Francisco, California, United States of America
| | - Cheryl L Willman
- University of New Mexico Cancer Center, Albuquerque, New Mexico, United States of America
| | - Kenneth J Kopecky
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
| | - Urte Gayko
- Nodality, Inc., South San Francisco, California, United States of America
| | - Santosh Putta
- Nodality, Inc., South San Francisco, California, United States of America
| | - Brent Louie
- Nodality, Inc., South San Francisco, California, United States of America
| | - Matt Westfall
- Nodality, Inc., South San Francisco, California, United States of America
| | - Norman Purvis
- Nodality, Inc., South San Francisco, California, United States of America
| | - David C Spellmeyer
- Nodality, Inc., South San Francisco, California, United States of America
| | - Carol Marimpietri
- Nodality, Inc., South San Francisco, California, United States of America
| | - Aileen C Cohen
- Nodality, Inc., South San Francisco, California, United States of America
| | - James Hackett
- Nodality, Inc., South San Francisco, California, United States of America
| | - Jing Shi
- Nodality, Inc., South San Francisco, California, United States of America
| | - Michael G Walker
- Nodality, Inc., South San Francisco, California, United States of America
| | - Zhuoxin Sun
- ECOG Coordinating Center, Frontier Science, Boston, Massachusetts, United States of America
| | - Elisabeth Paietta
- Montefiore Medical Center North Division, Bronx, New York, United States of America
| | - Martin S Tallman
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Larry D Cripe
- Indiana University Simon Cancer Center, Indianapolis, Indiana, United States of America
| | - Susan Atwater
- Stanford University, Palo Alto, California, United States of America
| | - Frederick R Appelbaum
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
| | - Jerald P Radich
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
| |
Collapse
|
3
|
Abstract
A male neonate presented with a high white cell count, an 11q23 translocation, and M5b leukemia. He was treated at 3 days of age with intensive combination chemotherapy after progressing despite exchange transfusions. The patient achieved complete remission at 28 days of age. Therapy was completed at the age of 6 months. At the time of this report, the patient is 17 months old and remains in remission. Twenty-nine patients with congenital acute myeloid leukemia were also reviewed. Twenty of these patients received varying therapies. Ten of the treated patients achieved complete remission; two died of toxicity; and eight died of progressive disease. Two patients had a translocation affecting 11q23. Congenital leukemia is a rare and usually fatal condition in patients without Down syndrome. The patient reported here shows that survival may be achieved with very intensive chemotherapy plus supportive care, despite extremely high white blood cell counts and unfavorable translocation.
Collapse
MESH Headings
- Adult
- Agriculture
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Asparaginase/administration & dosage
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 11/ultrastructure
- Chromosomes, Human, Pair 5/genetics
- Chromosomes, Human, Pair 5/ultrastructure
- Cytarabine/administration & dosage
- Dexamethasone/administration & dosage
- Exchange Transfusion, Whole Blood
- Female
- Granulocyte Colony-Stimulating Factor/therapeutic use
- Humans
- Idarubicin/administration & dosage
- Infant, Newborn
- Leukemia, Monocytic, Acute/congenital
- Leukemia, Monocytic, Acute/drug therapy
- Leukemia, Monocytic, Acute/genetics
- Leukemia, Monocytic, Acute/therapy
- Male
- Maternal Exposure
- Occupational Exposure
- Pesticides
- Remission Induction
- Thioguanine/administration & dosage
- Translocation, Genetic
- Treatment Outcome
- Vidarabine/administration & dosage
- Vidarabine/analogs & derivatives
Collapse
Affiliation(s)
- M C Fernandez
- Department of Pediatrics, University of California Medical School, University of California San Franciso, USA
| | | | | | | | | |
Collapse
|
4
|
Kogan SC, Lagasse E, Atwater S, Bae SC, Weissman I, Ito Y, Bishop JM. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci U S A 1998; 95:11863-8. [PMID: 9751756 PMCID: PMC21731 DOI: 10.1073/pnas.95.20.11863] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Chromosomal translocations involving the genes encoding the alpha and beta subunits of the Pebp2/Cbf transcription factor have been associated with human acute myeloid leukemia and the preleukemic condition, myelodysplasia. Inv(16)(p13;q22) fuses the gene encoding the beta subunit of Pebp2 to the MYH11 gene encoding a smooth muscle myosin heavy chain (Smmhc). To examine the effect of the inv(16)(p13;q22) on myelopoiesis, we used the hMRP8 promoter element to generate transgenic mice expressing the Pebp2betaSmmhc chimeric fusion protein in myeloid cells. Neutrophil maturation was impaired in PEBP2betaMYH11 transgenic mice. Although the transgenic mice had normal numbers of circulating neutrophils, their bone marrow contained increased numbers of immature neutrophilic cells, which exhibited abnormal characteristics. In addition, PEBP2betaMYH11 inhibited neutrophilic differentiation in colonies derived from hematopoietic progenitors. Coexpression of both PEBP2betaMYH11 and activated NRAS induced a more severe phenotype characterized by abnormal nuclear morphology indicative of granulocytic dysplasia. These results show that PEBP2betaMYH11 can impair neutrophil development and provide evidence that alterations of Pebp2 can contribute to the genesis of myelodysplasia.
Collapse
Affiliation(s)
- S C Kogan
- G. W. Hooper Foundation, University of California, San Francisco, CA 94143-0552, USA.
| | | | | | | | | | | | | |
Collapse
|
6
|
Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94:2551-6. [PMID: 9122233 PMCID: PMC20126 DOI: 10.1073/pnas.94.6.2551] [Citation(s) in RCA: 374] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The malignant cells of acute promyelocytic leukemia (APL) contain a reciprocal chromosomal translocation that fuses the promyelocytic leukemia gene (PML) with the retinoic acid receptor alpha gene (RAR alpha). To test the hypothesis that the chimera PMLRAR alpha plays a role in leukemogenesis, we expressed a PMLRAR alpha cDNA in myeloid cells of transgenic mice. PMLRAR alpha transgenic mice exhibited impaired neutrophil maturation early in life, which progressed at a low frequency over the course of several months to overt APL. Both the preleukemic state and the leukemia could be transplanted to nontransgenic mice, and the transplanted preleukemia could progress to APL. The APL recapitulated features of the human disease, including a response to retinoic acid. Retinoic acid caused the leukemic cells to differentiate in vitro and in vivo, eliciting remissions of both the preleukemic state and APL in mice. Our results demonstrate that PMLRAR alpha impairs neutrophil differentiation and initiates the development of APL. The transgenic mice described here provide an apparently accurate model for human APL that includes clear evidence of tumor progression. The model should be useful for exploring the molecular pathogenesis of APL and the mechanisms of the therapeutic response to retinoic acid, as well as for preclinical studies of therapeutic regimens.
Collapse
MESH Headings
- Animals
- Antineoplastic Agents/pharmacology
- Bone Marrow/pathology
- Cell Differentiation/drug effects
- Chromosomes, Human, Pair 15
- Flow Cytometry
- Humans
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/pathology
- Mice
- Mice, Transgenic
- Neoplasm Proteins
- Neutrophils/physiology
- Nuclear Proteins
- Promyelocytic Leukemia Protein
- Receptors, Retinoic Acid/biosynthesis
- Receptors, Retinoic Acid/genetics
- Recombinant Fusion Proteins/biosynthesis
- Retinoic Acid Receptor alpha
- Transcription Factors/biosynthesis
- Transcription Factors/genetics
- Translocation, Genetic
- Tretinoin/pharmacology
- Tumor Suppressor Proteins
Collapse
Affiliation(s)
- D Brown
- G.W. Hooper Foundation, Department of Biochemistry and Biophysics, University of California, San Francisco 94143-0552, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Automated leukocyte differential counting has resulted in a marked improvement of the precision of leukocyte subclass enumeration. With advancement of this technology, algorithms have been developed to identify samples that require manual microscopic review. Complex flagging algorithms permit acceptable false-positive rates with effective use of microscopic review to identify significant morphologic abnormalities. Current literature indicates that the leukocyte differential is a poor case-finding index in both outpatient and inpatient populations. Development of highly automated technology has led to test over-utilization because of ease of performance despite recognized limitations in identifying clinically significant abnormalities. Enumeration of hematopoietic stem cells in harvested peripheral blood or bone marrow is critical for determining whether transplanted cells will produce adequate engraftment. Hematopoietic precursors express the CD34 antigen, are present as rare events in unmobilized blood, and are found in increased numbers after mobilization with chemotherapy with or without G-CSF. Flow cytometric detection of CD34+ cells is more rapid and precise than cell culture techniques and results are available in time to determine if further cell harvesting procedures will be necessary. CD34+ cell concentrations correlate with granulocyte-macrophage colony-forming unit counts as well as with time to engraftment. Although intralaboratory precision in measuring these infrequent events may be good, comparisons between different laboratories using aliquots of the same sample have yielded more variable results. Problems in determining precise and reproducible CD34+ cell concentrations may be due to nonspecific antibody binding, insufficient signal intensity of true positive events, differences in monoclonal antibodies and their fluorochrome conjugates, or failure of the total absolute leukocyte count to accurately reflect the population used for CD34 analysis.
Collapse
Affiliation(s)
- S Atwater
- Department of Laboratory Medicine, University of California, San Francisco 94143-0100, USA
| | | |
Collapse
|
8
|
Mehrotra B, George TI, Kavanau K, Avet-Loiseau H, Moore D, Willman CL, Slovak ML, Atwater S, Head DR, Pallavicini MG. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 1995; 86:1139-47. [PMID: 7542497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Leukemia may be viewed as a clonal expansion of blast cells; however, the role of primitive cells and/or stem cells in disease etiology and progression is unclear. We investigated stem cell involvement in leukemia using fluorescence in situ hybridization (FISH), immunofluorescence labeling of hematopoietic subpopulations, and flow cytometric analysis/sorting to discriminate and quantify cytogenetically aberrant stem cells in 12 acute myeloid leukemia (AML) and three myelodysplastic (MDS) specimens. Flow cytometric analysis and sorting were used to discriminate and collect a primitive subpopulation enriched in stem cells expressing CD34+ and lacking CD33 and CD38 (CD34+lin-). A subpopulation containing progenitors and differentiating myeloid cells expressed CD34, CD33, and CD38 (CD34+lin+). Nine specimens contained less than 10% CD34+ cells and, thus, were considered to be CD34- leukemias. Mature lymphoid, myeloid, and erythroid subpopulations were sorted on the basis of antigen-linked immunofluorescence. Cytogenetically aberrant cells in sorted subpopulations were identified using FISH with enumerator probes selected on the basis of diagnosis karyotype. Cytogenetically aberrant CD34+lin- cells were present at frequencies between 9% and 99% in all specimens. CD34+lin- cytogenetically aberrant cells comprised between 0.05% and 11.9% of the marrow/blood specimens. Cytogenetically aberrant CD34+lin+ cells constituted 0.01% tp 56% of the marrow/blood population. These data demonstrate that aberrant cells are present in primitive CD34+ stem cell compartments, even in CD34- leukemias. Stem cell involvement was confirmed further by sorting lymphoid and erythroid subpopulations from eight specimens in which the predominant leukemic population lacked lymphoid/erythroid differentiation markers. In these specimens, as well as in multiple lineages, suggests involvement of a cell(s) with multilineage capabilities. The ability of aberrant CD34+lin- stem cells to contribute to clonal and compartment expansion within immunofluorescently defined subpopulations was evaluated to explore the functional phenotype of aberrant CD34+lin- cells. Analysis of compartment size and aberrant cell frequency suggests that frequency of cytogenetically aberrant stem cells is uncoupled from compartment size. These data suggest that cytogenetically aberrant cells in the primitive compartment show varying abilities to expand primitive compartments. Cytogenetically aberrant CD34+lin- cells precede the blast subpopulation in hierarchical maturation and may in some cases by considered preleukemic, requiring maturation or additional mutations before transformation (eg, compartmental expansion) occurs.
Collapse
Affiliation(s)
- B Mehrotra
- Department of Laboratory Medicine, University of California, San Francisco 94103, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Stages I and II extranodal head and neck lymphomas treated between 1969 and 1986 were reviewed to determine prognosis and recurrence patterns. Forty-four patients had low-grade lymphoma, with 57% remaining disease free (median survival, 7.2 years). Radiotherapy provided long-term disease-free survival and palliation in the majority of patients. Relapse did not adversely affect survival. Eighty-eight patients had intermediate- or high-grade lymphoma, with 42% remaining disease free (median survival, 2.4 years). Treatment with radiotherapy alone was inadequate. Combined radiotherapy and anthracycline-containing chemotherapy appeared to be superior. Extranodal sites of first relapse were common. Central nervous system relapse was common with primary tumors located above the pterygopalatine line. Central nervous system staging and prophylactic therapy is warranted in patients with tumors above the pterygopalatine line.
Collapse
Affiliation(s)
- G V Burton
- Department of Medicine, Duke University Medical Center, Durham, NC
| | | | | | | |
Collapse
|